US Congress Unlikely to Prevent Hemp THC Product Ban
The United States Congress is not expected to block a forthcoming federal ban on certain hemp‑derived THC products slated to take effect in November, according to leaders of the Marijuana Policy Project (MPP). The impending regulatory shift could substantially reshape the hemp cannabinoid market, which has operated under the parameters set by the 2018 Farm Bill.
New Regulatory Framework and Its Scope
The 2018 Farm Bill defined hemp as cannabis containing less than 0.3 percent delta‑9 THC by dry weight. Late last year, additional language was inserted into a federal spending measure that broadens how the THC threshold is measured. Under the revised rule, the 0.3 percent limit now applies to the combined amount of delta‑9 THC, delta‑8 THC, and THCA. Moreover, consumer products will be capped at 0.4 milligrams of total THC per container, and synthetically produced or chemically converted cannabinoids will be restricted.
Karen O’Keefe, MPP’s State Policies Director, pointed out that Senator Mitch McConnell (R‑KY) championed the changes, citing worries about unregulated sales and packaging within the hemp sector. She told Marijuana Moment that, rather than filling the regulatory gap left since 2018 with a balanced framework, Congress effectively prohibited most hemp products beginning in November.
Adam Smith, MPP’s Executive Director, noted that significant cannabis‑related legislation is unlikely from the current Congress. While Representative Andy Barr (R‑KY) is expected to introduce a hemp‑focused bill, its passage is considered doubtful. Smith suggested any adjustments might be limited to tweaking THC thresholds or adding narrow provisions for beverages, with the administration reportedly favoring a slightly higher allowance to accommodate full‑spectrum extracts.
Projected Impact on the Hemp Industry
If the ban proceeds as scheduled, many businesses that have built their models around selling THC‑laden hemp products could face severe financial strain. Smith described the outlook as a “financial disaster for companies built around selling THC products from hemp,” warning that numerous firms may be forced to shut down, pivot to non‑intoxicating offerings, or continue operating under federal illegality—similar to state‑legal marijuana enterprises.
- Companies may need to cease operations, shift to alternative product lines, or risk federal prosecution.
- Such a shift could hinder access to banking services and create immigration complications for non‑U.S. citizen employees working in the cannabinoid space.
- Kevin Caldwell, MPP’s Southeast Legislative Manager, warned of potential declines in state tax revenue, reduced consumer access, and an increase in arrests as these items are reclassified as marijuana and subject to corresponding penalties.
O’Keefe highlighted that the 0.4 milligram total THC cap per container is especially restrictive, affecting not only intoxicating edibles but also topicals and full‑spectrum CBD formulations that often exceed this threshold. While limiting synthetic cannabinoids addresses unknown health risks, the measure is part of a broader tightening that could curtail a wide range of hemp‑derived goods.
Broader Policy Considerations and Market Dynamics
MPP leaders argue for a comprehensive cannabinoid policy that safeguards public health while preserving lawful access. Smith noted that the proliferation of delta‑8 and synthetic cannabinoids is, in part, a byproduct of existing federal prohibitionist policies. He also referenced recent surveys indicating that teen cannabis use has declined despite market expansion, countering concerns about heightened youth exposure.
Observers from the alcohol industry are monitoring the situation with mixed perspectives. Distillers generally oppose the introduction of THC‑infused beverages, whereas some distributors see potential market opportunities, creating a complex lobbying environment. Caldwell concluded that, while minor legislative tweaks may occur, a sweeping repeal of the hemp THC product ban or a major opening for intoxicating hemp products appears improbable, leaving farmers and businesses facing uncertainty as planting seasons begin.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid‑derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
Source: Here
